SCCHN tumor expression of the truncated form of EGFR, EGFR variant III (vIII), which lacks the ligand binding domain, occurs in up to 40% of SCCHN tumors and confers resistance to EGFR-targeted monoclonal antibodies in SCCHN preclinical models [15]. Here, EGFR is linked to head and neck squamous cell carcinoma.